Asthma Clinical Trial
Official title:
Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing
Infants will be enrolled into this study in one of three groups. First, there will be a group of full term infants with no history of wheezing. Second, there will be a group of infants receiving a ct scan that is non-respiratory related. Third, there will be a group of infants that are born full term but have a history of wheezing of at least 3 episodes. The three groups will be compared to see if there is a difference in lung function, lung structure and lung size. Besides comparing the testing results we will be evaluating environmental and inherited characteristics. There are 2 purposes of this study. The first purpose is: To determine whether asymptomatic groups of infants at high risk for wheezing (Environmental tobacco smoke (ETS) exposure, Fm Asthma, male Gender) have fixed or reversible airway narrowing. The second purpose of this study is: To determine the relative contributions of fixed and reversible airway narrowing in infants with recurrent symptomatic wheezing, and to determine whether fixed and reversible airway narrowing is related to ETS exposure, Fm Asthma, and male Gender.
Among asymptomatic healthy infants decreased airway function is found in infants exposed to
environmental tobacco smoke (ETS) or with history of family asthma (Fm Asthma), or male
gender. These infants are at significantly greater risk of wheezing during infancy. These
findings indicate that genetic and environmental factors affect the mechanical determinants
of airway function and that among healthy infants variations of these mechanical
determinants contribute to the increased risk of developing airway obstruction severe enough
to result in clinical symptoms of wheezing. The mechanisms of reduced airway function in
these at risk infants are not known. In adults reduced airway function is a result of airway
narrowing, increased airway compliance, or decreased pulmonary elastic recoil. The same is
thought to be true in infants. The cause of airway narrowing may be functional (reversible
by bronchodilators) or structural (fixed, not reversible by bronchodilators) or have
components of both. Fixed determinants of airway narrowing include small absolute airway
size, thickened airway wall, decreased elastic recoil, and small airway size relative to
lung volume. Reversible determinants include airway hyper-responsiveness and inflammation.
Understanding the alterations of airway function that increase the risk of airway disease
will be decisive in the development of strategies for the prevention and treatment of
wheezing in infants and children, and hence, a reduction of morbidity and mortality.
It is not known whether infants with recurrent wheezing have persistent airway narrowing
when not acutely symptomatic, and whether airway function in these infants is related to ETS
exposure, Fm Asthma, and male gender. When recurrently wheezy infants are asymptomatic,
airway function may be low or normal, and low airway function may be fixed or reversible
with a bronchodilator. It is important to determine whether these infants have functional
and structural abnormalities when they are not acutely symptomatic, and to determine how
lung structure relates to lung function. Only then can we design effective therapeutic
interventions for recurrently symptomatic infants, as well as, design early intervention
strategies.
The Specific aims of this project are:
Specific Aim # 1: To determine whether asymptomatic groups of infants at high risk for
wheezing (Environmental tobacco smoke (ETS) exposure, Fm Asthma, male Gender) have fixed or
reversible airway narrowing.
Specific Aim # 2: To determine the relative contributions of fixed and reversible airway
narrowing in infants with recurrent symptomatic wheezing, and to determine whether fixed and
reversible airway narrowing is related to ETS exposure, Fm Asthma, and male Gender.
We propose to answer these important questions of lung function and structure in infants
using state of the art methodologies
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|